Precise diagnosis and treatment system for thyroid-associated eye disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study will develop a deep learning model that integrates multimodal data from imaging and ocular examinations to provide automated diagnosis, staging, grading, treatment suggestions, and prognosis predictions for thyroid-associated ophthalmopathy (TAO). Researchers will collect standardized eye images and clinical exam data from both patients with TAO and control participants without eyelid disorders to train and validate the system. Observational methods will be used to compare model outputs to clinical labels and current diagnostic standards, with cases meeting exclusion criteria (pupil/cornea disorders, prior eye injury) omitted. The goal is to create a tool that supports clinicians by synthesizing image and exam data into consistent, actionable reports.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* normal participants without eyelid disorders (control group)
* patients with thyroid-associated ophthalmopathy (TAO group)
* cooperative participants

Exclusion Criteria:

* participants with pupil or cornea disorders
* participants with history of eye injury

Where it's running

• Juan Ye
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Juan Ye
• Email: yejuan@zju.edu.cn
• Phone: +86-571-87783897

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining Tocilizumab and Flupentixol-Melitracen for Thyroid Eye Disease Treatment

  This study is testing if combining two medications, Tocilizumab and Flupentixol-Melitracen, can help people with thyroid eye disease feel better and improve their eye symptoms.

  Recruiting Phase 4 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT06927375

• Multiparametric prediction models for moderate to severe thyroid-associated eye disease

  This project will try to build and test combined imaging and lab-marker models to predict outcomes in adults with moderate to severe thyroid-associated ophthalmopathy.

  Recruiting Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT06590220

• Comparing short and standard radiation therapy for thyroid eye disease

  This study is testing if fewer sessions of radiation therapy can help people with moderate to severe thyroid eye disease just as well as the standard number of sessions, while also making their experience better.

  Recruiting Phase 3 Mahidol University · Bangkok Noi · NCT06392906

• Evaluating linsitinib for thyroid eye disease

  This study is testing if a new drug called linsitinib can help people with moderate to severe thyroid eye disease who haven't improved with other treatments.

  Recruiting at 2 sites Phase 2/3 Sling Therapeutics, Inc. · Miami, Florida and 1 other locations · NCT06112340

• Evaluating doxycycline for treating Thyroid Associated Ophthalmopathy

  This study is testing if doxycycline can help people with Thyroid Associated Ophthalmopathy feel better and improve their eye symptoms.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT05112211

• Comparing Sirolimus and Corticosteroids for Thyroid Eye Disease

  This study tests whether Sirolimus can be a safer and more effective treatment for people with moderate-to-severe thyroid eye disease compared to traditional corticosteroids.

  Recruiting Phase 2 Haukeland University Hospital · Bergen, Hordaland · NCT04936854

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.